Correlation Between Xilio Development and Monopar Therapeutics
Can any of the company-specific risk be diversified away by investing in both Xilio Development and Monopar Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xilio Development and Monopar Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Xilio Development and Monopar Therapeutics, you can compare the effects of market volatilities on Xilio Development and Monopar Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xilio Development with a short position of Monopar Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xilio Development and Monopar Therapeutics.
Diversification Opportunities for Xilio Development and Monopar Therapeutics
-0.39 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Xilio and Monopar is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Xilio Development and Monopar Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Monopar Therapeutics and Xilio Development is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xilio Development are associated (or correlated) with Monopar Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Monopar Therapeutics has no effect on the direction of Xilio Development i.e., Xilio Development and Monopar Therapeutics go up and down completely randomly.
Pair Corralation between Xilio Development and Monopar Therapeutics
Considering the 90-day investment horizon Xilio Development is expected to generate 3.53 times more return on investment than Monopar Therapeutics. However, Xilio Development is 3.53 times more volatile than Monopar Therapeutics. It trades about 0.13 of its potential returns per unit of risk. Monopar Therapeutics is currently generating about 0.08 per unit of risk. If you would invest 72.00 in Xilio Development on November 27, 2024 and sell it today you would earn a total of 22.00 from holding Xilio Development or generate 30.56% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Xilio Development vs. Monopar Therapeutics
Performance |
| Timeline |
| Xilio Development |
| Monopar Therapeutics |
Xilio Development and Monopar Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Xilio Development and Monopar Therapeutics
The main advantage of trading using opposite Xilio Development and Monopar Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xilio Development position performs unexpectedly, Monopar Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will offset losses from the drop in Monopar Therapeutics' long position.| Xilio Development vs. Connect Biopharma Holdings | Xilio Development vs. Tyra Biosciences | Xilio Development vs. RAPT Therapeutics | Xilio Development vs. Mineralys Therapeutics, Common |
| Monopar Therapeutics vs. Anebulo Pharmaceuticals | Monopar Therapeutics vs. Acrivon Therapeutics, Common | Monopar Therapeutics vs. Pmv Pharmaceuticals | Monopar Therapeutics vs. Molecular Partners AG |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Complementary Tools
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |